Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Spiriva Safe in Long-Term Treatment: BI, Pfizer
October 6, 2008
- Price Settlement Rate as of End July 48.5%
October 6, 2008
- Boceprevir Effective for Treatment-Naive Hepatitis C Patients: Schering-Plough
October 6, 2008
- TOPICS／Bayer, Onyx Launch Global Liver Cancer Educational Program
October 6, 2008
- Korosho Issues Vision for Medical Devices Industry
October 6, 2008
- Will Distribution Practices Be Improved? Part 4
October 6, 2008
- NHO to Jointly Purchase Reagents through Bids in All Blocks
October 6, 2008
- BUSINESS NEWS IN BRIEF
October 6, 2008
- Increased Use of Generics Makes Management of Drugs Brought by Patients More Difficult
October 6, 2008
- SEMINAR／Expiration of Patents to Weigh Heavily on Japanese Pharmas
October 6, 2008
- Most Patients Consult Doctors, Not Pharmacists, Regarding Selection of Generics
October 6, 2008
- FDA Continues to Review NDA for Prasugrel
October 6, 2008
- Preparedness for New PAL Differs Greatly among OTC Drug Makers
October 6, 2008
- Pure Pharma Business Model Approaching the End: Mr K. Masuzoe
September 29, 2008
- Avastin Effective in Patients with or without K-ras Gene Mutation
September 29, 2008
- Quintiles to Provide Lab Data Directly Comparable with Those from Other Countries
September 29, 2008
- Mylan to Increase Number of MRs to 300, Open 4 More Offices
September 29, 2008
- Astellas Ties Up with Maxygen to Develop Drugs for Autoimmune Diseases, Transplant Rejection
September 29, 2008
- More Prescriptions than Expected Prohibit Use of Generics: Mr Urushibata
September 29, 2008
- Erbitux Launched by Merck Serono and Bristol-Myers
September 29, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…